Market Cap 1.86B
Revenue (ttm) 123.67M
Net Income (ttm) -38.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -31.24%
Debt to Equity Ratio 0.00
Volume 1,155,100
Avg Vol 1,237,326
Day's Range N/A - N/A
Shares Out 84.48M
Stochastic %K 59%
Beta 1.56
Analysts Strong Sell
Price Target $33.17

Company Profile

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of i...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 949 2643
Address:
321 Harrison Avenue, Suite 900, Boston, United States
LabPsycho
LabPsycho Jul. 15 at 2:25 PM
$GLUE @oceanbleu yeah, I think the maket peak was a few days after the 4th of July and now the slow unwinding, esp for many biotechs that are up 100-2000% in the past 16 months...lots of room to retrace and still leave many with incredible yearly gains. I am looking at when some of these started their huge runs and thinking selling might start after investors can claim long term (vs short term) capital gains (after 1 yr of holding). Good luck
0 · Reply
oceanbleu
oceanbleu Jul. 13 at 7:26 PM
$GLUE I posted this chart a few times in last 4 weeks with recommended partial profit taking at 23/24.9 area. The 1st support is at 20.7-20.9 and for now down side is limited to 19.3$.
0 · Reply
ap20
ap20 Jul. 10 at 4:28 PM
$GLUE Added.
0 · Reply
LabPsycho
LabPsycho Jul. 10 at 2:03 PM
$GLUE Hmm...this, IMO, disproportionate dumping with volume suggests to me the ole hackneyed cliche 'somebody knows something'
3 · Reply
ap20
ap20 Jul. 9 at 7:39 PM
$GLUE Stick with GLUE.
0 · Reply
MuchMillions
MuchMillions Jul. 9 at 6:52 PM
$GLUE last chance to scoop this under $25
0 · Reply
MuchMillions
MuchMillions Jul. 9 at 6:51 PM
0 · Reply
justiceforb_85
justiceforb_85 Jul. 9 at 2:27 AM
$GLUE intrigued by MRT-6160. Do they have a favorable partnership on this with $NVS?
2 · Reply
ajmrtxl
ajmrtxl Jul. 8 at 3:23 PM
$GLUE 's latest squeeze play
0 · Reply
MuchMillions
MuchMillions Jul. 7 at 4:26 PM
$GLUE shorts are cooked
0 · Reply
Latest News on GLUE
Monte Rosa Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Monte Rosa Therapeutics Earnings release: Q1 2026


Monte Rosa Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Monte Rosa Therapeutics Quarterly report: Q1 2026


Monte Rosa Therapeutics Slides: Corporate presentation

May 6, 2026, 7:00 AM EDT - 2 months ago

Monte Rosa Therapeutics Slides: Corporate presentation


Monte Rosa Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Monte Rosa Therapeutics Proxy statement: Proxy filing


Monte Rosa Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Monte Rosa Therapeutics Proxy statement: Proxy filing


Monte Rosa Therapeutics reports Q4 collaboration revenue $2.78M

2026-03-17T15:05:52.000Z - 4 months ago

Monte Rosa Therapeutics reports Q4 collaboration revenue $2.78M


Monte Rosa Therapeutics Annual report: Q4 2025

Mar 17, 2026, 7:00 AM EDT - 4 months ago

Monte Rosa Therapeutics Annual report: Q4 2025


Monte Rosa Therapeutics Earnings release: Q4 2025

Mar 17, 2026, 7:00 AM EDT - 4 months ago

Monte Rosa Therapeutics Earnings release: Q4 2025


Monte Rosa Therapeutics Slides: Corporate presentation

Mar 16, 2026, 7:00 AM EDT - 4 months ago

Monte Rosa Therapeutics Slides: Corporate presentation


Monte Rosa Therapeutics files automatic mixed securities shelf

2026-02-11T21:40:21.000Z - 5 months ago

Monte Rosa Therapeutics files automatic mixed securities shelf


Monte Rosa Therapeutics announces $200M common stock offering

2026-01-07T21:05:48.000Z - 6 months ago

Monte Rosa Therapeutics announces $200M common stock offering


Monte Rosa Therapeutics Transcript: Study Result

Jan 7, 2026, 8:00 AM EST - 6 months ago

Monte Rosa Therapeutics Transcript: Study Result


Monte Rosa Therapeutics Press release: Study Result

Jan 7, 2026, 8:00 AM EST - 6 months ago

Monte Rosa Therapeutics Press release: Study Result


Monte Rosa Therapeutics Slides: Study Result

Jan 7, 2026, 8:00 AM EST - 6 months ago

Monte Rosa Therapeutics Slides: Study Result


Monte Rosa Therapeutics announces Phase 1 data of MRT-8102

2026-01-07T12:10:51.000Z - 6 months ago

Monte Rosa Therapeutics announces Phase 1 data of MRT-8102


Monte Rosa Therapeutics Transcript: Study Result

Dec 16, 2025, 8:00 AM EST - 7 months ago

Monte Rosa Therapeutics Transcript: Study Result


Monte Rosa Therapeutics Press release: Study Result

Dec 16, 2025, 8:00 AM EST - 7 months ago

Monte Rosa Therapeutics Press release: Study Result


Monte Rosa Therapeutics Slides: Study Result

Dec 16, 2025, 8:00 AM EST - 7 months ago

Monte Rosa Therapeutics Slides: Study Result


Monte Rosa Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Monte Rosa Therapeutics Earnings release: Q3 2025


Monte Rosa Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Monte Rosa Therapeutics Quarterly report: Q3 2025


Monte Rosa Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Monte Rosa Therapeutics Earnings release: Q2 2025


Monte Rosa Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Monte Rosa Therapeutics Quarterly report: Q2 2025


Monte Rosa Therapeutics Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Earnings release: Q1 2025


Monte Rosa Therapeutics Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Quarterly report: Q1 2025


Monte Rosa Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Proxy statement: Proxy Filing


Monte Rosa Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Proxy statement: Proxy Filing


Monte Rosa Therapeutics Earnings Call Transcript: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Earnings Call Transcript: Q4 2024


Monte Rosa Therapeutics Annual report: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Annual report: Q4 2024


Monte Rosa Therapeutics Earnings release: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Earnings release: Q4 2024


Monte Rosa Therapeutics Slides: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Slides: Q4 2024


Monte Rosa Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Monte Rosa Therapeutics Quarterly report: Q3 2024


Monte Rosa Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Monte Rosa Therapeutics Earnings release: Q3 2024


This Biotech Stock Has Doubled Its Value Today—Here's Why

Oct 28, 2024, 3:06 PM EDT - 1 year ago

This Biotech Stock Has Doubled Its Value Today—Here's Why


Monte Rosa Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 9:30 AM EDT - 2 years ago

Monte Rosa Therapeutics Quarterly report: Q2 2024


Monte Rosa Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 9:30 AM EDT - 2 years ago

Monte Rosa Therapeutics Earnings release: Q2 2024


Monte Rosa Therapeutics Announces Leadership Team Promotions

May 30, 2024, 7:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Announces Leadership Team Promotions


Monte Rosa Therapeutics Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Quarterly report: Q1 2024


Monte Rosa Therapeutics Earnings release: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Earnings release: Q1 2024


Monte Rosa Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Proxy statement: Proxy Filing


Monte Rosa Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Proxy statement: Proxy Filing


Monte Rosa Therapeutics Earnings release: Q4 2023

Mar 14, 2024, 8:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Earnings release: Q4 2023


Monte Rosa Therapeutics Annual report: Q4 2023

Mar 14, 2024, 8:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Annual report: Q4 2023


LabPsycho
LabPsycho Jul. 15 at 2:25 PM
$GLUE @oceanbleu yeah, I think the maket peak was a few days after the 4th of July and now the slow unwinding, esp for many biotechs that are up 100-2000% in the past 16 months...lots of room to retrace and still leave many with incredible yearly gains. I am looking at when some of these started their huge runs and thinking selling might start after investors can claim long term (vs short term) capital gains (after 1 yr of holding). Good luck
0 · Reply
oceanbleu
oceanbleu Jul. 13 at 7:26 PM
$GLUE I posted this chart a few times in last 4 weeks with recommended partial profit taking at 23/24.9 area. The 1st support is at 20.7-20.9 and for now down side is limited to 19.3$.
0 · Reply
ap20
ap20 Jul. 10 at 4:28 PM
$GLUE Added.
0 · Reply
LabPsycho
LabPsycho Jul. 10 at 2:03 PM
$GLUE Hmm...this, IMO, disproportionate dumping with volume suggests to me the ole hackneyed cliche 'somebody knows something'
3 · Reply
ap20
ap20 Jul. 9 at 7:39 PM
$GLUE Stick with GLUE.
0 · Reply
MuchMillions
MuchMillions Jul. 9 at 6:52 PM
$GLUE last chance to scoop this under $25
0 · Reply
MuchMillions
MuchMillions Jul. 9 at 6:51 PM
0 · Reply
justiceforb_85
justiceforb_85 Jul. 9 at 2:27 AM
$GLUE intrigued by MRT-6160. Do they have a favorable partnership on this with $NVS?
2 · Reply
ajmrtxl
ajmrtxl Jul. 8 at 3:23 PM
$GLUE 's latest squeeze play
0 · Reply
MuchMillions
MuchMillions Jul. 7 at 4:26 PM
$GLUE shorts are cooked
0 · Reply
Wemby5566
Wemby5566 Jul. 7 at 2:20 PM
$GLUE Back to business. We are in H2. Only things that matters are the 8102 readout, the 6160 P2 initiations and Zeus trial results. Nothing else matters
0 · Reply
LabPsycho
LabPsycho Jul. 7 at 1:30 PM
$GLUE @telomerase I just did a quick check of a few other protein degrader stocks (GLUE, NRIX, CCCC) and another seemingly legit computational chemistry stock (ABSI) and they all seem to have about 20% short, all seemingly show increase in short over time. That was based on quick glance and memory of about how many shares outstanding they have. Someone check me and add to the list with more precise numbers please
1 · Reply
LabPsycho
LabPsycho Jul. 7 at 1:18 PM
$GLUE @telomerase - I do not see anything unusual about the % short GLUE - aren't many biotechs about 20% short?
2 · Reply
LabPsycho
LabPsycho Jul. 7 at 1:17 PM
$GLUE @telomerase Corrections - 1. I do not think I have ever suggested to buy or sell a stock. I post my predictions and reasons pros / cons why I think a stock could go up or down. 2. I started posting years ago, thinking it would go down from 12 to 6 (it got to 4 ish) then ramped up the posts when GLUE was in the 4's based in part on their 2025 SCIENCE article thinking it might turn around. Most importantly, I am always hoping for counterpoints / corrections to my posts
0 · Reply
telomerase
telomerase Jul. 7 at 12:08 PM
$GLUE for those posting the old chestnut about short squeeze... highly shorted stocks statistically UNDER perform. And it's not a good sign when short interest just keeps going up. https://economics.mit.edu/sites/default/files/publications/Short%20Interest,%20Institutional%20Ownership.pdf https://www.nasdaq.com/market-activity/stocks/glue/short-interest
4 · Reply
telomerase
telomerase Jul. 7 at 12:03 PM
$GLUE It's hilarious reading this board calling LabPsycho a "bear"... he was telling everyone to buy this in the 5s.
2 · Reply
Wemby5566
Wemby5566 Jul. 7 at 1:48 AM
$GLUE LabPsycho do you actually own any shares of this company or what dude. Show me the gains of your perfect predictions. Here are mine
1 · Reply
LabPsycho
LabPsycho Jul. 7 at 12:45 AM
$GLUE @Wemby5566 What an exceptionally ignorant, foolish and self-stultifying comment - YIKES! Have you looked at any of my posts, esp the past year about GLUE? When this was $4!? How about my posts actually bringing GLUE Science cover article image to and animated life using advanced computational chemistry and supercomputer to do an atomically accurate molecular dynamic simultion of GLUE drug!? And posted here! How about all of the perfect predictions I had about the move of this stock and fortelling of events that would occur with unrivaled accuracy and precision and posted here that multibillion dollar hedge funds can not yet even dream of doing. I have many post proving my jaw dropping, eye-popping precision that back up that claim. Unmatched by any hedge fund ever. Hopefully you have blocked me - your comment tells me you dont deserve the knowledge I am sharing here for free.
2 · Reply
LabPsycho
LabPsycho Jul. 6 at 7:31 PM
$GLUE Not sure what I think of some insiders selling recently. On one hand GLUE has gone up 500% in 9 months so why not? Job well done. On the other hand if a big pharma licensing deal was on the table / in discussions, wouldnt they wait?
2 · Reply
LabPsycho
LabPsycho Jul. 2 at 2:13 PM
$GLUE @oceanbleu I expect a bit of churning here $24.60 +/- $0.80 then effortless float up to $31
2 · Reply
oceanbleu
oceanbleu Jul. 2 at 1:31 PM
$GLUE ended being a nice 40% gain on the initial suggested trade , 16.3$ entry and target 1 profit taking at 23/24.9 area. Momentum looks good on hourly time frame so it is quite likely it manages tohold above 22.8 and get through the 25.5$ last resistance pivot. If it does i have two levels of interest at 26.6 and 30$.
0 · Reply
Wemby5566
Wemby5566 Jul. 1 at 2:42 PM
$GLUE Shorts Iike LabPsycho have been getting rocked. Love it
1 · Reply